GSK - Ticker AI Digest

GSK 06:01

GSK plc

Blenrep approved by US FDA in multiple myeloma

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSKs Blenrep (belantamab mafodotin-blmf) has been approved by the US FDA for treating relapsed/refractory multiple myeloma in patients who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval is based on the DREAMM-7 phase III trial, which demonstrated a 51% reduction in the risk of death and a tripled median progression-free survival (31.3 months vs. 10.4 months) compared to a daratumumab-based triplet. Blenrep is the only anti-BCMA therapy accessible in community settings, where 70% of patients receive care, and it comes with a streamlined REMS program to enhance patient safety and reduce administrative burden. GSK is advancing clinical trials to explore Blenreps potential in earlier treatment lines, including newly diagnosed patients. The drug is already approved in several regions, including the EU, UK, Japan, Canada, Switzerland, and Brazil, with applications under review in other markets, including China. This approval addresses a significant unmet need in multiple myeloma treatment, offering improved outcomes for patients with limited options.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK receives expanded Shingrix approval in China

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced on October 14, 2025, that its shingles vaccine, Shingrix (Recombinant Zoster Vaccine or RZV), has received expanded regulatory approval in China. The China National Medical Products Administration (NMPA) approved Shingrix for the prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression. This approval builds on the existing indication for adults aged 50 and over, making Shingrix the first and only vaccine approved for this high-risk population in China.

Shingles, caused by the reactivation of the varicella zoster virus, affects approximately six million people annually in China, with immunocompromised individuals at higher risk. The disease can cause severe pain and complications like post-herpetic neuralgia, significantly impacting quality of life. The expanded approval ensures protection for vulnerable populations, addressing a critical unmet need.

The NMPA’s decision was supported by six clinical trials involving immunocompromised patients, including those with blood cancers, solid tumors, HIV, and transplant recipients. GSK’s Senior Vice President, Sanjay Gurunathan, highlighted the milestone as a step toward protecting vulnerable groups and shifting healthcare focus toward disease prevention.

Shingrix is a non-live, recombinant subunit vaccine combining glycoprotein E with the AS01B adjuvant system, designed to overcome age-related immune decline. It is not indicated for preventing primary varicella infection (chickenpox). GSK emphasized its commitment to innovation and collaboration with regulatory bodies to advance public health.

**Key Points**

Shingrix approved in China for adults aged 18+ at high risk of shingles due to immunodeficiency/immunosuppression.

First and only vaccine for this population in China, expanding on existing approval for adults aged 50+.

Addresses six million annual shingles cases in China, with immunocompromised individuals at higher risk.

Supported by six clinical trials in high-risk populations.

GSK aims to protect vulnerable groups and promote disease prevention.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK ADC gets orphan drug designation in the EU

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSKs antibody-drug conjugate (ADC), GSK227, has received **Orphan Drug Designation (ODD)** from the European Medicines Agency (EMA) for treating **pulmonary neuroendocrine carcinoma (NEC)**, including **small-cell lung cancer (SCLC)**. This designation is based on promising early clinical data from the **ARTEMIS-001 trial**, showing durable responses in patients with extensive-stage SCLC (ES-SCLC), a condition with limited treatment options and poor outcomes.

GSK227, targeting the **B7-H3 protein**, is being developed for multiple solid tumors, including lung, prostate, and colorectal cancers. This ODD marks the **fourth regulatory designation** for GSK227, following **EMA’s Priority Medicines (PRIME) designation** and **FDA’s Breakthrough Therapy Designations** for ES-SCLC and osteosarcoma.

GSK’s global **Phase III trial** for GSK227 in relapsed ES-SCLC began in August 2025. The company aims to accelerate ADC development to address significant unmet needs in cancer treatment, with an estimated 250,000 SCLC diagnoses and 200,000 deaths annually worldwide.

**Key Points**

GSK227 receives EU Orphan Drug Designation for pulmonary NEC, including SCLC.

Fourth regulatory designation highlights its potential across multiple solid tumors.

Phase III trial underway for relapsed ES-SCLC, targeting a high unmet need.

GSK continues to advance ADC development with transformational potential.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK ADC gets orphan drug designation in the EU

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSKs antibody-drug conjugate (ADC), GSK227, has received **Orphan Drug Designation (ODD)** from the European Medicines Agency (EMA) for treating **pulmonary neuroendocrine carcinoma (NEC)**, including **small-cell lung cancer (SCLC)**. This designation is based on promising early clinical data from the **ARTEMIS-001 trial**, showing durable responses in patients with extensive-stage SCLC (ES-SCLC), a condition with limited treatment options and poor outcomes.

GSK227, targeting the **B7-H3 protein**, is being developed for multiple solid tumors, including lung, prostate, and colorectal cancers. This ODD marks the **fourth regulatory designation** for GSK227, following **EMA’s Priority Medicines (PRIME) designation** and **FDA’s Breakthrough Therapy Designations** for ES-SCLC and osteosarcoma.

GSK’s global **Phase III trial** for GSK227 in relapsed ES-SCLC began in August 2025. The company aims to accelerate ADC development to address significant unmet needs in cancer treatment, with an estimated 250,000 SCLC diagnoses and 200,000 deaths annually worldwide.

**Key Points**

GSK227 receives EU Orphan Drug Designation for pulmonary NEC, including SCLC.

Fourth regulatory designation highlights its potential across multiple solid tumors.

Phase III trial underway for relapsed ES-SCLC, targeting a high unmet need.

GSK continues to advance ADC development with transformational potential.

Go Back To AI Charts

GSK 06:01

GSK plc

Blenrep approved by US FDA in multiple myeloma

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSKs Blenrep (belantamab mafodotin-blmf) has been approved by the US FDA for treating relapsed/refractory multiple myeloma in patients who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval is based on the DREAMM-7 phase III trial, which demonstrated a 51% reduction in the risk of death and a tripled median progression-free survival (31.3 months vs. 10.4 months) compared to a daratumumab-based triplet. Blenrep is the only anti-BCMA therapy accessible in community settings, where 70% of patients receive care, and it comes with a streamlined REMS program to enhance patient safety and reduce administrative burden. GSK is advancing clinical trials to explore Blenreps potential in earlier treatment lines, including newly diagnosed patients. The drug is already approved in several regions, including the EU, UK, Japan, Canada, Switzerland, and Brazil, with applications under review in other markets, including China. This approval addresses a significant unmet need in multiple myeloma treatment, offering improved outcomes for patients with limited options.

Go Back To AI Charts

GSK 06:01

GSK plc

GSK receives expanded Shingrix approval in China

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced on October 14, 2025, that its shingles vaccine, Shingrix (Recombinant Zoster Vaccine or RZV), has received expanded regulatory approval in China. The China National Medical Products Administration (NMPA) approved Shingrix for the prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression. This approval builds on the existing indication for adults aged 50 and over, making Shingrix the first and only vaccine approved for this high-risk population in China.

Shingles, caused by the reactivation of the varicella zoster virus, affects approximately six million people annually in China, with immunocompromised individuals at higher risk. The disease can cause severe pain and complications like post-herpetic neuralgia, significantly impacting quality of life. The expanded approval ensures protection for vulnerable populations, addressing a critical unmet need.

The NMPA’s decision was supported by six clinical trials involving immunocompromised patients, including those with blood cancers, solid tumors, HIV, and transplant recipients. GSK’s Senior Vice President, Sanjay Gurunathan, highlighted the milestone as a step toward protecting vulnerable groups and shifting healthcare focus toward disease prevention.

Shingrix is a non-live, recombinant subunit vaccine combining glycoprotein E with the AS01B adjuvant system, designed to overcome age-related immune decline. It is not indicated for preventing primary varicella infection (chickenpox). GSK emphasized its commitment to innovation and collaboration with regulatory bodies to advance public health.

**Key Points**

Shingrix approved in China for adults aged 18+ at high risk of shingles due to immunodeficiency/immunosuppression.

First and only vaccine for this population in China, expanding on existing approval for adults aged 50+.

Addresses six million annual shingles cases in China, with immunocompromised individuals at higher risk.

Supported by six clinical trials in high-risk populations.

GSK aims to protect vulnerable groups and promote disease prevention.

Go Back To AI Charts